Avanos Medical delivered strong Specialty Nutrition Systems growth and closed its acquisition of Nexus Medical, advancing innovation in neonatal and pediatric nutrition despite ongoing tariff pressures.

Global pharma companies set a new record by investing $48.5B in partnerships with Chinese biotechs in the first half of 2025, led by innovations in oncology and next-gen therapeutics.

Eli Lilly announces a $3 billion investment for a new oral medications manufacturing facility in the Netherlands, aiming to expand its European supply chain, create jobs, and deploy next-generation manufacturing technology.

Akeso has secured a fourth Breakthrough Therapy Designation from China NMPA for ivonescimab in first-line TNBC, expediting development and regulatory pathways.

UPS has finalized its $1.6 billion acquisition of Andlauer Healthcare Group, significantly expanding its pharma logistics infrastructure and services throughout North America.

The European Commission has awarded Bavarian Nordic a new framework procurement contract for up to 8 million doses of smallpox/mpox vaccines, enhancing Europe’s disease preparedness.

Mallinckrodt announces new research presentations on terlipressin for hepatorenal syndrome at the 2025 AASLD meeting, underscoring ongoing innovation in rare liver disease therapeutics.

Boryeong expands its global CDMO business by partnering with Joulik Pharma to supply original cytotoxic anti-cancer drug Alimita across seven Southeast Asian nations.

A new industry report reveals that the U.S. pharmaceutical sector is witnessing a $350 billion manufacturing investment boom, but growth is being threatened by critical labor shortages, tariffs, and shifting policy landscapes.

Fosun Pharma posts Q3 2025 results showing robust growth in innovative drug revenue, significant R&D investment, international regulatory progress, and strategic finance initiatives, underscoring the firm's leadership in Asia’s pharmaceutical technology sector.